21 Apr 2014

Keppra (Levetiracetam) - España

ATC: N03AX
NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
OTHER ANTIEPILEPTICS
Keppra

Last Updated on 21 Apr 2014 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Keppra Indication

Keppra está indicado como monoterapia en el tratamiento de las crisis de inicio parcial con o sin generalización secundaria en adultos y adolescentes de 16 años de edad o mayores con un nuevo diagnóstico de epilepsia.

Keppra está indicado como terapia concomitante
- en el tratamiento de las crisis de inicio parcial con o sin generalización secundaria en adultos, adolescentes, niños y lactantes desde 1 mes de edad con epilepsia.
- en el tratamiento de las crisis mioclónicas en adultos y adolescentes mayores de 12 años con Epilepsia Mioclónica Juvenil.
- en el tratamiento de las crisis tónico-clónicas generalizadas primarias en adultos y adolescentes mayores de 12 años con Epilepsia Generalizada Idiopática.

Keppra Generic Name

Levetiracetam

Type

POM

Summary Product Characteristics (SPCs) Links
Resumen de las Características del Producto - Keppra (external site)

Related Learning Zones

Obesity CME series

Obesity CME series

This European Obesity Initiative CME series contains three online modules, which are ideal for healthcare professionals looking to widen their understanding of obesity as a serious medical illness. Each module is EACCME-accredited and free to complete. Successful completion of the series will earn participants a combined total of 5 European CME credits (ECMECs).

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Selected content related to Keppra (Levetiracetam)

Journals

  • Safety of Levetiracetam in Paediatrics: A Systematic Review.
    Egunsola O, Choonara I, Sammons HM.
    PLoS One Mar 2016

    Objective: To identify adverse events (AEs) associated with Levetiracetam (LEV) in children.

    Methods: Databases EMBASE (1974-February 2015) and Medline (1946-February 2015) were searched for articles in which paediatric patients (≤18 years)
     

  • The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population.
    Tekgül H, Gencpinar P, Çavuşoğlu D, Dündar NO.
    Seizure - European Journal of Epilepsy Feb 2016

    Purpose: The purpose of this study was to assess the efficacy and safety of levetiracetam monotherapy in a pediatric population.

    Method: A retrospective review was performed of the charts of 351
     

  • Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
    Vari MS, Pinto F, Mencaroni E, Giudizioso G, Minetti C, La Neve A et al.
    Clinical Drug Investigation Jan 2016

    Background and objective: Concerns that antiepileptic brand-to-generic interchange results in disruption of seizure control are widespread. The objective of this study was to evaluate the safety and tolerability of the
     

  • Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures.
    Suresh SH, Chakraborty A, Virupakshaiah A, Kumar N.
    Epilepsy Research and Treatment Dec 2015

    Introduction: Levetiracetam (LEV) is a newer antiepileptic drug with better pharmacokinetic profile. Currently, it is frequently used for the treatment of partial seizures. The present study was undertaken to compare
     

News

Guidelines

Keppra Marketing Information

Keppra Generic Name
Levetiracetam
Marketing Company
UCB Pharma SA
Drug Type
POM
Date of Issue, Marketing Authority

29/09/2000

Related Drugs - Neurological Disorders

Back to top